Drug Availability Update

Further to DrugAlert volume 712, HPS Pharmacies wish to give notice that Roche is continuing to experience a supply interruption for Actemra^® as follows:

Actemra^® Vials
Tocilizumab 200mg/10mL
ARTG 149404

Normal supplies of Actemra^® IV 200mg vials are expected to return by the start of September 2021.

The following supply interruptions are also anticipated:

• Actemra^® IV 400mg vials – from August 2021 to end-January 2022
• Actemra^® 162mg/0.9mL pre-filled syringe – from mid-August 2021 to mid-October 2021
•  Actemra^® 162mg/0.9mL pre-filled pen, ACTPen autoinjector – from September 2021 to mid-October 2021.

This is a global supply interruption related to increased demand as a result of the COVID-19 pandemic. The Therapeutic Goods Administration (TGA) advises prescribers to consider the current shortage of tocilizumab when prescribing, particularly when initiating therapy for the registered indications.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Roche on (02) 9454 9000, or your pharmacist at HPS Pharmacies.